Diagnosis, treatment and survival of patients with hepatorenal syndrome: A survey on daily medical practice

• Published in: Journal of hepatology Vol. 55; no. 6; pp. 1241 - 1248
• Main Authors: Salerno, Francesco, Cazzaniga, Massimo, Merli, Manuela, Spinzi, Giancarlo, Saibeni, Simone, Salmi, Andrea, Fagiuoli, Stefano, Spadaccini, Antonio, Trotta, Elisa, Laffi, Giacomo, Koch, Maurizio, Riggio, Oliviero, Boccia, Sergio, Felder, Martina, Balzani, Simona, Bruno, Savino, Angeli, Paolo
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier B.V 01.12.2011; Elsevier
• Subjects: Abdomen; Aged; Albumins - therapeutic use; Ascites; Biological and medical sciences; Cohort Studies; Female; Gastroenterology and Hepatology; Gastroenterology. Liver. Pancreas. Abdomen; Hepatorenal Syndrome - classification; Hepatorenal Syndrome - diagnosis; Hepatorenal Syndrome - drug therapy; Hepatorenal Syndrome - mortality; Humans; Italy - epidemiology; Kidney; Liver. Biliary tract. Portal circulation. Exocrine pancreas; Male; Medical sciences; Middle Aged; Midodrine; Other diseases. Semiology; Portal hypertension; Prevalence; Prospective Studies; Terlipressin; Treatment Outcome; Vasoconstrictor Agents - therapeutic use; Italy; red blood cells; RCT; receiver operating characteristics; LVP; HRS; INR; Kidney; Terlipressin; GFR; large-volume paracentesis; RBC; white blood cells; Portal hypertension; WBC; hepatocellular carcinoma; TIPS; SBP; International Ascites Club; glomerular filtration rate; transjugular intrahepatic portosystemic shunt; ROC; HCC; IAC; Midodrine; randomized controlled trial; International Normalized Ratio; RF; MELD; hepatorenal syndrome; model of end-stage liver disease; renal failure; spontaneous bacterial peritonitis; Ascites; Agonist; Prognosis; Vasodilator agent; Portal circulation disease; Cardiovascular disease; Vascular disease; Neurohypophyseal hormone; Gastroenterology; Vasoconstrictor agent; Diagnosis; Hepatorenal syndrome; Kidney disease; Human; Urinary system disease; Effusion; Sympathomimetic; Survival; Vasopressin; Survey; Treatment; Abdominal disease; Digestive diseases; Antihypertensive agent
• ISSN: 0168-8278; 1600-0641
• DOI: 10.1016/j.jhep.2011.03.012

Background & Aims Hepatorenal syndrome (HRS) is a severe complication of cirrhosis with ascites. The International Ascites Club recommended strict diagnostic criteria and treatment with vasoconstrictors and albumin. Aim of this prospective cohort study was to investigate the prevalence of HRS, diagnostic criteria, treatment and 3-month outcome in the daily-clinical-practice. Methods Two-hundred-fifty-three patients with cirrhosis and renal failure consecutively admitted to 21 Italian hospitals were recruited. Results The prevalence of HRS was 45.8% (30% type-1 and 15.8% type-2). In 36% of cases HRS was presumed because not all diagnostic criteria could be fulfilled. In 8% of cases HRS was superimposed on an organic nephropathy. Patients with HRS type-1 were younger and showed higher leukocyte count, higher respiratory rates, and worse liver function scores. Sixty-four patients with HRS type-1 received vasoconstrictors (40 terlipressin and 24 midodrine/octreotide). A complete response was obtained in 19 cases (30%) and a partial response in 13 (20%). Age was the only independent predictor of response ( p = 0.033). Three-month survival of patients with HRS type-1 was 19.7%. Survival was better in patients who responded to therapy. Age ( p = 0.017), bilirubin ( p = 0.012), and creatinine increase after diagnostic volume expansion ( p = 0.02) independently predicted death. The mortality rate was 97% among patients with at least two negative predictors. Conclusions The diagnostic criteria of HRS in our daily-clinical-practice could not be completely fulfilled in one third of cases. The treatment with vasoconstrictors and albumin was widely implemented. Mortality was strongly predicted by simple baseline variables.